ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Single-cell immune subtyping of basophils in head and neck squamous cell carcinoma and a prognostic model based on bulk RNA sequencing.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe precise contribution of basophils to cancer development and advancement remains undefined. Our research sought to delineate the immune subtypes of basophils in head and neck squamous cell carcinoma (HNSCC) and to develop a robust prognostic model.
methodsSingle-cell and bulk transcriptomic data from the TCGA-HNSC and the GEO (GSE41613, GSE139324) were integrated. Basophil subtypes and their signature genes were identified. Samples were subjected to unsupervised consensus clustering based on basophil-related differentially expressed genes to define immune subtypes. A prognostic model was constructed and its performance validated in external datasets. The biological function of the key gene DHRS2 was investigated through in vitro experiments.
resultsSingle-cell analysis identified heterogeneous basophil populations in HNSCC, classified into distinct subtypes. Cluster 1 displayed a low immune infiltration phenotype. Using basophil signature genes, TCGA-HNSC samples were stratified into two subtypes with significant survival differences. A 12-gene prognostic model with good predictive performance was developed. High-risk patients showed high tumor purity along with downregulated immune checkpoint and HLA gene expression, indicative of active immune evasion. Experimentally, the key model gene DHRS2 was highly expressed in HNSCC, and its knockdown suppressed cell proliferation, migration, and invasion while inducing apoptosis.
conclusionThe study characterizes basophil immune subtypes in HNSCC and establishes a robust basophil-related prognostic model that effectively identifies high-risk patients, suggesting the potential pro-tumorigenic gene DHRS2 as a therapeutic target in HNSCC.
Indexed as
Identifiers
42507213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.